Research programme: single domain antibody therapeutics - AdAlta

Drug Profile

Research programme: single domain antibody therapeutics - AdAlta

Alternative Names: AD 114; AD-214; i-bodies

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AdAlta
  • Developer AdAlta; Lonza; University of Sydney
  • Class Antibodies; Antifibrotics; Proteins
  • Mechanism of Action CXCR4 receptor antagonists; G protein-coupled receptor modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Fibrosis; Kidney disorders; Retinal disorders

Most Recent Events

  • 18 Apr 2018 AdAlta plans a phase I trial for Idiopathic pulmonary fibrosis in 2019
  • 21 Feb 2018 AdAlta plans to complete an initial first-in-human study in Idiopathic pulmonary fibrosis (In volunteers), in 2018
  • 19 Feb 2018 AdAlta plans to complete final preclinical toxicology studies for Idiopathic pulmonary fibrosis (IPF) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top